Eisai and Biogen's Joint Development, Lecanemab, Progresses in EU Regulatory Review for Alzheimer's Treatment
Jul 27, 2024
ESALF Equities
FDA Approves Eisai's LEQEMBI® Maintenance Dosing Application for Early Alzheimer's Treatment
Jun 10, 2024